Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids

Fig. 5

Hedgehog signaling inhibitor promoted sensitivity to sorafenib in CD44-positive HCC PDOs. a 4 HCC PDOs were treated with sorafenib in the presence or absence of GANT61 for 6 days. Cell viability was determined using CellTiter-Glo reagents. b IF images of CD44 in HCC cell lines (Hep3B, SNU423 and BEL7402). Scale bar: 25 μm. c Representative bright-field images of 2 HCC cell lines (Hep3B and BEL7402) treated with DMSO, sorafenib (10 μM), GANT61 (5 μM) or a combination of sorafenib and GANT61 for 6 days are shown. After fixation with 100% ethanol, the colonies were stained with crystal violet. The number of colonies was counted. d Representative bright-field images of 2 HCC cell lines (Hep3B and 7402) treated with DMSO, sorafenib (10 μM), GANT61 (5 μM) or a combination of sorafenib and GANT61 for 6 days are shown. After fixation with 100% ethanol, the invasive cells were stained with crystal violet. The number of migrated cells was counted. Scale bar: 500 μm. e The viability of SNU423 and BEL7402 HCC cells was tested and treated with sorafenib, purmorphamine, GANT61 or the combination as indicated for 48 h. f The viability of SNU423 and BEL7402 HCC cells was tested, after treatment with sorafenib, GANT61 or a combination of sorafenib and GANT61. The Chou-Talalay combination index (CI) was calculated. (*p < 0.05, *** p < 0.001, **** p < 0.0001, P < 0.05 is considered statistically significant)

Back to article page